[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2015005313A - Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil. - Google Patents

Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.

Info

Publication number
MX2015005313A
MX2015005313A MX2015005313A MX2015005313A MX2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A MX 2015005313 A MX2015005313 A MX 2015005313A
Authority
MX
Mexico
Prior art keywords
elution
mops
biomolecules
mes
mobile phase
Prior art date
Application number
MX2015005313A
Other languages
English (en)
Inventor
Daniel Cummings
Veena Warikoo
Rahul Godawat
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015005313A publication Critical patent/MX2015005313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/16—Holders for containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a métodos para purificar o enriquecer una biomolécula utilizando resinas multimodales y un tampón de elución que contiene un tampón de Good.
MX2015005313A 2012-10-24 2013-10-23 Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil. MX2015005313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717880P 2012-10-24 2012-10-24
PCT/US2013/066319 WO2014066471A1 (en) 2012-10-24 2013-10-23 Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers

Publications (1)

Publication Number Publication Date
MX2015005313A true MX2015005313A (es) 2016-04-06

Family

ID=49554488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005313A MX2015005313A (es) 2012-10-24 2013-10-23 Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.

Country Status (13)

Country Link
US (2) US20150275195A1 (es)
EP (1) EP2911759B1 (es)
CN (3) CN104884147A (es)
AU (3) AU2013334644B2 (es)
CA (1) CA2888824C (es)
DK (1) DK2911759T3 (es)
ES (1) ES2988082T3 (es)
HK (1) HK1222868A1 (es)
HU (1) HUE068316T2 (es)
MX (1) MX2015005313A (es)
PL (1) PL2911759T3 (es)
SG (2) SG11201502918RA (es)
WO (1) WO2014066471A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015005313A (es) * 2012-10-24 2016-04-06 Genzyme Corp Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.
BR112015021495A2 (pt) * 2013-03-08 2017-07-18 Genzyme Corp fabricação contínua integrada de substâncias de droga de proteína terapêutica
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
BR112020013197A8 (pt) 2017-12-29 2022-11-08 Baxalta Inc Métodos de purificação de vírus adenoassociado
CN108479110A (zh) * 2018-04-10 2018-09-04 深圳市菲鹏生物制药股份有限公司 一种细胞培养液脱色剂及脱色方法
MX2021002314A (es) 2018-08-31 2021-04-28 Genzyme Corp Resina de cromatografia esteril y uso de la misma en procedimientos de produccion.
DE102020214647A1 (de) 2020-11-20 2022-05-25 DIL Deutsches Institut für Lebensmitteltechnik e.V. Anthocyanhaltiges Extraktpulver und Verfahren zur Herstellung

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347322A (en) * 1981-01-12 1982-08-31 Nabisco Brands, Inc. Chromatographic process for enzyme purification
US4663288A (en) * 1985-05-22 1987-05-05 Nabisco Brands, Inc. Process for purification of enzymes
EP0935651B1 (en) 1996-09-13 2004-12-29 Transkaryotic Therapies, Inc. THERAPY FOR alpha-GALACTOSIDASE A DEFICIENCY
JP2008538181A (ja) * 2005-03-30 2008-10-16 ネオス テクノロジーズ インコーポレイテッド 昆虫細胞系において増殖させたペプチドを生産するための製造方法
US20080090278A1 (en) * 2006-03-31 2008-04-17 Toyo Boseki Kabushiki Kaisha Method for enhancing stability of a composition comprising soluble glucose dehydrogenase (gdh)
PL2167526T3 (pl) 2007-07-11 2011-09-30 Novo Nordisk As Oczyszczanie czynnika VIII za pomocą żywicy o mieszanej funkcji lub wielofunkcyjnej
EP2242762B1 (en) * 2008-01-18 2015-12-16 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
KR101700722B1 (ko) 2008-06-24 2017-01-31 옥타파마 아게 응고 인자 ｖｉｉｉ을 정제하는 방법
US20110166332A1 (en) 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
CA2697999C (en) * 2009-04-24 2013-04-30 Werner Hoelke A stabilized aqueous alpha-galactosidase composition and methods relating thereto
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011088225A1 (en) * 2010-01-15 2011-07-21 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
ES2740825T3 (es) 2010-03-30 2020-02-06 Octapharma Ag Un procedimiento de purificación de proteínas dependientes de vitamina K
AU2011234532B2 (en) * 2010-03-30 2015-04-09 Octapharma Ag Process for the purification of a Growth Factor Protein
EP2635600B1 (en) * 2010-11-05 2017-06-21 F. Hoffmann-La Roche AG Optimized method for antibody capturing by mixed mode chromatography
WO2012062753A1 (de) * 2010-11-09 2012-05-18 Qiagen Gmbh Verfahren und vorrichtung zur isolierung und reinigung von doppelsträngigen nukleinsäuren
WO2012173876A1 (en) * 2011-06-13 2012-12-20 Merck Sharp & Dohme Corp. Methods of purification of native or mutant forms of diphtheria toxin
JP6356607B2 (ja) * 2011-11-02 2018-07-11 ジェネンテック， インコーポレイテッド オーバーロード／溶出クロマトグラフィー
MX2015005313A (es) * 2012-10-24 2016-04-06 Genzyme Corp Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.
CA2890358C (en) * 2012-11-13 2020-02-11 Ace Biosciences A/S Purification of recombinant human galactocerebroside .beta.-galactosidase (rhgalc)
DK2994485T3 (en) * 2013-05-06 2018-04-23 Sanofi Sa CONTINUOUS MULTIPLE STEP PROCEDURE FOR PURIFICATION OF ANTIBODIES

Also Published As

Publication number Publication date
AU2013334644B2 (en) 2018-07-12
AU2020203008A1 (en) 2020-05-28
AU2018241214A1 (en) 2018-11-01
SG11201502918RA (en) 2015-05-28
US11203747B2 (en) 2021-12-21
SG10201901695RA (en) 2019-03-28
CN104884147A (zh) 2015-09-02
CA2888824C (en) 2021-02-02
CN105777862A (zh) 2016-07-20
AU2013334644A1 (en) 2015-05-07
US20150275195A1 (en) 2015-10-01
DK2911759T3 (da) 2024-09-16
AU2018241214B2 (en) 2020-02-06
US20200131493A1 (en) 2020-04-30
WO2014066471A1 (en) 2014-05-01
PL2911759T3 (pl) 2024-10-28
CA2888824A1 (en) 2014-05-01
AU2020203008B2 (en) 2022-06-16
CN111172135A (zh) 2020-05-19
ES2988082T3 (es) 2024-11-19
EP2911759B1 (en) 2024-07-17
EP2911759A1 (en) 2015-09-02
HK1222868A1 (zh) 2017-07-14
HUE068316T2 (hu) 2024-12-28
AU2018241214B9 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
MX2015005313A (es) Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX354243B (es) Polipeptidos anticuerpos que antagonizan cd40.
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
PH12014502406A1 (en) Anti-il-23p19 antibodies
MY174025A (en) Azole silane compound, surface treatment solution, surface treatment method, and use thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX2013005793A (es) Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos.
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
IN2014CN04160A (es)
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
WO2013149111A3 (en) Anti-tlr4 antibodies and uses thereof
EP2992021A4 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
SI3200822T1 (sl) Vezavne molekule, posebno antiteles, vezanih na L1CAM (CD171)
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
MX336369B (es) Uso de acido elagico como agentes anticaspa.
SI2938609T1 (sl) Postopek za pripravo 1-((1,3)dioksolan-4-ilmetil)-1H-pirazol-3-ilamina
WO2013093627A3 (en) In silico affinity maturation
GB201307574D0 (en) Method of synthesising ADC's using affinity resins